Beta-blockers disrupt mitochondrial bioenergetics and increase radiotherapy efficacy independently of beta-adrenergic receptors in medulloblastoma

Maïlys Rossi,a Julie Talbot,b Patricia Piris,a Marion Le Grand,a Marie-Pierre Montero,a Mélanie Matteudi,a Emilie Agamian-Couquiaud,c Romain Appay,d Céline Keime,d Daniel Williamson,d Duje Buric,e Véronique Bourgarel,d Laetitia Padovani,h Steven C. Clifford,f Olivier Ayrault,b Eddy Pasquier,a,i Nicolas André,a,i,j* and Manon Carrée a*

aCentre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, CNRS, Inserm, Institut Paoli Calmettes, Marseille, France
bInstitut Curie, Inserm, CNRS, Université Paris-Saclay, Orsay, France
cPlateforme ICEP (CRCM), Aix-Marseille Université, CNRS, Inserm, Institut Paoli Calmettes, Marseille, France
dService d’anatomie pathologique et de neuropathologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France
ePlateforme GenomEast, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS, Inserm, Université de Strasbourg, Illkirch-Graffenstaden, France
fWolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom
gInstitut Méditerranéen de Biodiversité et d’Ecologie marine et continentale (IMBIE), Aix-Marseille Université, CNRS, IRD, Avignon Université, Marseille, France
hService de Radiothérapie, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France
iMetronomics Global Health Initiative, Marseille, France
jService d’Hématologie & Oncologie Pédiatrique, Timone Hospital, AP-HM, Marseille, France

Summary
Background Medulloblastoma is the most frequent brain malignancy of childhood. The current multimodal treatment comes at the expense of serious and often long-lasting side effects. Drug repurposing is a strategy to fast-track anti-cancer therapy with low toxicity. Here, we showed the ability of β-blockers to potentiate radiotherapy in medulloblastoma with bad prognosis.

Methods Medulloblastoma cell lines, patient-derived xenograft cells, 3D spheroids and an innovative cerebellar organotypic model were used to identify synergistic interactions between β-blockers and ionising radiations. Gene expression profiles of β-adrenergic receptors were analysed in medulloblastoma samples from 240 patients. Signaling pathways were explored by RT-qPCR, RNA interference, western blotting and RNA sequencing. Medulloblastoma cell bioenergetics were evaluated by measuring the oxygen consumption rate, the extracellular acidification rate and superoxide production.

Findings Low concentrations of β-blockers significantly potentiated clinically relevant radiation protocols. Although patient biopsies showed detectable expression of β-adrenergic receptors, the ability of the repurposed drugs to potentiate ionising radiations did not result from the inhibition of the canonical signaling pathway. We highlighted that the efficacy of the combinatorial treatment relied on a metabolic catastrophe that deprives medulloblastoma cells of their adaptive bioenergetics capacities. This led to an overproduction of superoxide radicals and ultimately to an increase in ionising radiations-mediated DNA damages.

Interpretation These data provide the evidence of the efficacy of β-blockers as potentiators of radiotherapy in medulloblastoma, which may help improve the treatment and quality of life of children with high-risk brain tumours.

Funding This study was funded by institutional grants and charities.

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: Beta-blockers; Bioenergetics; Medulloblastoma; Radiotherapy; Therapeutic combinations
Introduction

Medulloblastomas (MB) are embryonal tumours of the cerebellum and the most common malignant brain tumours of childhood. They have been classified into four main subtypes. WNT MB, has the most favorable clinical prognosis but accounts for only 10% of cases. SHH MB, and the other Non-WNT/Non-SHH subgroups (Group 3 and Group 4) are somewhat more aggressive and more frequently metastatic, with a poorer prognosis. The current multimodal treatment combines surgery, radiotherapy and chemotherapy. Overall, long-term survival is now achieved in 60-75% of patients but it comes at the expense of serious and often long-lasting side effects that can reduce independence and significantly alter the quality of life of survivors. High-risk MB are treated with radiation therapy with a cumulative dose of 54 Gy for irradiation of the posterior cerebellar fossa and additional 36 Gy for craniospinal irradiation. Although these doses are not always sufficient to control tumour progression, they cannot be increased as both acute toxicities and the cognitive and endocrinological sequelae would be too important in the long-term. Since these sequelae are even greater in young patients, radiotherapy is contraindicated in children under 3-5 years of age depending on countries. Therefore, new treatment options for MB patients are needed to improve the response to radiotherapy, with the aim of increasing the therapeutic benefits of ionising irradiation (IR) and/or reducing its doses and associated deleterious side effects while maintaining its efficacy.

Drug repurposing consists in using already-approved drugs for indications that differ from those for which the drugs were originally developed. Toxicity and pharmacokinetic profiles are well documented, so that repurposed drugs can directly enter Phase II clinical trials. By reducing the time, expenses and risks associated with the development process, drug repurposing is an attractive strategy in anticancer therapeutics.

One of the promising pharmacological classes to be repurposed is the \( \beta \)-adrenergic antagonists, or \( \beta \)-blockers. They are widely known for their regulatory properties in cardiovascular dysfunctions. To date, the use of propranolol for the treatment of severe hemangiomas of infancy represents one of the most successful examples of drug repurposing, with higher efficacy and fewer toxic side effects than the previous standard of care. Since then, our preclinical and clinical studies have shown that \( \beta \)-blockers can increase the efficacy of chemotherapy in drug-refractory cancers, including paediatric tumours such as neuroblastoma. \( \beta \)-blockers can impair fundamental biologic processes underlying tumour progression, such as cell proliferation, migration, tumour angiogenesis and metastasis. \( \beta \)-blockers have also been shown to sustain the response of irradiated gastric adenocarcinoma, colon adenocarcinoma or non-small cell lung cancer (NSCLC) in \textit{vivo}, and improve survival outcomes in adult patients with intracranial meningiomas and NSCLC. These recent examples provide a strong rationale to combine \( \beta \)-blockers with radiotherapy in paediatric solid tumours, where...
this type of combination has never been evaluated. Here, we provide evidence that β-blockers can improve the efficacy of IR in MB cell lines and PDX-derived cells, by disrupting mitochondrial bioenergetics, independently of the β-adrenergic receptors.

Material and methods

Cell culture

The human MB cell lines DAoy (RRID: CVCL_1167), D341 Med (RRID: CVCL_0018) and D283 Med (RRID: CVCL_1155) were obtained from the ATCC biobank. HDMB-03 cells (RRID: CVCL_S506), were kindly provided by Sonia Martial and Gilles Pagès from the Institute for Research on Cancer and Aging (Nice, France). The human ONS-76 (RRID: CVCL_1624) and UW228-2 (RRID: CVCL_0572) cell lines were kindly provided by Janet Lindsey and Steven Clifford from the Wofson Childhood Cancer Research Center (New Castle, UK). DAOY and UW228-2 cells are representatives of the WNT group; HD-MB03, D341 Med, D283 Med and ONS-76 cells are representatives of non-WNT/non-SHH MB.

All the cells were maintained at 37°C and 5% CO2. DAOY and D283 Med cells were grown in MEM medium (Gibco, ref. 12561056) supplemented with 10% fetal calf serum (FCS; Gibco, ref. 26140079) and 1% Non-Essential Amino Acids (Gibco, ref. 11140035) and of 1% PS. ONS-76 cells are representatives of non-WNT/non-SHH MB.

Patient-derived xenografts culture

Patient-derived xenografts (PDXs) were generated from primary human MB samples and were maintained into the subcapsular fat pad of Nude mice (RRID: MGI:15649750) as previously described.26 G3-PDX3, G3-PDX7 and SHH-PDX12 correspond to group 3 ICN-MB-PDX-3, group 3 ICN-MB-PDX-7 and SHH ICN-MB-PDX-12, respectively. For in vitro cultures, tumour cells were purified from the PDX using an enzymatic dissociation followed by a Percoll density gradient separation and cultured as previously described.26

Drugs and reagents

The β-blockers were resuspended in dimethyl sulfoxide (DMSO). Stock solutions were stored at -20°C for Nebivolol (50 mM, Sigma-Aldrich, ref. NI9135) and Carvedilol (50 mM, Sigma-Aldrich, ref. #C3993) and at -80°C for Propranolol (150 mM, Selleckchem, ref. S4076). The antioxidants Mito-TEMPO (MT) and Troxerutin (TROX) were resuspended in DMSO. Stock solutions were stored at -20°C. The solutions are diluted in culture medium ex-temporaneously for the experiments.

Irradiation of MB cells, spheroids and organotypic cultures

Exposure to IR of the different culture models was performed in the Radiotherapy Department of Pr. Cowen (Timone Hospital, AP-HM, France). Water-equivalent RW3 phantom with a chamber adaptation plate was used for therapy dosimetry. Cells, spheroids and organotypic cultures were exposed to doses ranging from 1.8 Gy to 10 Gy, using the Synergy MLCi Elekta® linear accelerator with a beam of 6 MV and a flow rate of 400 UM/min. The PDX cells were irradiated in the RadExp platform of the Curie Institute on the X-Rad 320 equipment (Precision X-ray irradiation).

Cell growth and survival assays

Cell viability assays were performed as previously described.18 Briefly, the human MB cells were seeded in flat bottom 96-well microplates (2,000 cells/well for DAOY, ONS-76 and UW228-2; 9,000 cells/well for HD-MB03 and D283 Med; 12,000 cells/well for D341 Med) for 24 h. Cells were then exposed to β-blockers alone or in combination with IR for 72 h. Metabolic activity was detected by addition of Alamar Blue and spectrophotometric analysis using a PHERAstar FS multi-Plate Reader (BMG LABTECH; λex 540 nm / λem 590 nm). IC50 values were determined as previously described.18

For IncuCyte experiments (RRID:SCR_019874), SHH MB tumour cells were plated in 96-well plates (5,000 cells/well for murine SHH-MB and 7,500 cells/well for ICN-MB-PDX-12), pre-coated with poly-D-lysine (EMD Millipore, ref. A-003-E) and Matrigel (BD
Biosciences, ref. 354234). The next day, tumour cells were treated with a range of concentrations of β-blockers or the control, as indicated in figures. Propidium iodide (PI, Sigma Aldrich; 0.3 µg/ml) was also added to the medium to evaluate cell death. Then, the plates were scanned for phase contrast and PI staining during 72-96 h, using the IncuCyte® live cell analysis system with a 4X objective. Proliferation was measured using quantitative kinetic processing metrics from time-lapse image acquisition and showed as percentage of culture confluence over time. For the PI staining, the percentage of PI positive cells was divided by the percentage of cell confluence over time, thus indicating the level of dead cells in each well.

For the CellTiter-Glo® Luminescent Cell Viability Assay, Group 3 MB tumour cells were cultured in neurospheres in round bottom 96-well plates (5,000 cells/well). Tumour cells were then treated either 1) once with a range of concentrations of β-blockers or 2) daily with β-blockers and/or IR for five consecutive days. Then, the cell viability was evaluated 72 h later using the CellTiter-Glo® Luminescent Cell Viability Assay according to the manufacturer’s instructions (Promega Corporation, ref. G7570).

**Spheroid growth assay**

DsRed-expressing MB cells were plated in round bottom 96-well microplates (1,200 cells/well for HD-MB03 – 1,500 cells/well for UW228-2 and DAOY – 2,000 cells/well for ONS-76, D283 Med and D341 Med) in a culture medium containing 10% FBS and 20% methyl cellulose (Sigma-Aldrich, ref. M7027) for 72 h. Spheroids were then daily treated with β-blockers and/or IR for five days. Spheroid growth was quantified over time by acquisition of DsRed fluorescence signal using the PHERAtag™ FS multi-plate reader (λex 580 nm/λem 620 nm - fluorescence signal acquisition with a 15 × 15 matrix scanning mode).

**Sample preparation and immunohistochemistry**

Samples were fixed overnight at 4°C with 4% formaldehyde and prepared for paraffin inclusion using automated tissue processor ASP 300 (RRID:SCR_018916). Dehydration, clarification, and infiltration steps were performed by successive absolute ethanol, histolemon and paraffin baths. After FFPE-embedding, samples were cut at 1µm-thickness with HM340E microtome (Thermo Scientific). Hematoxylin Eosin Safran staining was performed using automated H&E staining Dako CoverStainer.

Ki-67- and γH2AX-immunohistochemistry was carried out with rabbit anti-Ki67 antibody (RRID: AB_443209) and with mouse anti-γH2AX antibody (Merck Millipore, ref. JW301) on a Ventana Discovery XT (RRID:SCR_018643). After deparaffinisation, antigen retrieval was performed with Citrate-based buffer pH 6.5 (RiboCC Solution, CC2, ref. 760-107). The primary antibodies were incubated for 20 min at 37°C then an OmniMap anti-Rabbit HRP Detection Kit (ref. 760-149) was used with DAB. Finally, the counterstaining was done with hematoxylin and slides were cleaned, dehydrated and coverslipped with permanent mounting media. The microscopic analysis of the tissues was carried out by the pathologists of the Neuropathology Department (Timone Hospital, AP-HM, France).

**Western-blot**

Cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 8), 150 mM NaCl, 1% Triton X-100, 0.1% SDS) to which was extemporaneously added a cocktail of phosphatase and protease inhibitors (Sigma-Aldrich, ref. PPC010). Protein concentration was determined using a Protein Assay Dye Reagent Concentrate (Bio-Rad, ref. #5000006EDU) according to the Bradford method. Proteins (30 µg) were separated by polyacrylamide-SDS gel (10% Mini-PROTEAN® TGX™ Precast Gels, Bio-Rad, ref. 4561034) and were transferred on nitrocellulose membrane (GE Healthcare Life Sciences). Primary antibodies used were directed against COX2, β-actin or γH2AX (RRID: AB_2571729, RRID: AB_2242334 and RRID: AB_2799949, respectively). Secondary antibody coupled to peroxidase (RRID: AB_2099233 for anti-rabbit, or RRID: AB_330924 for anti-mouse IgG antibody) were used for revelation, performed using the Luminata chemiluminescence detection kit (Millipore, ref. WBLUC0100). Images were acquired using the G-BOX.
phosphoimager (Ozyme) and signal quantification was realised by Image J® software (RRID:SCR_003070).

**Measurement of superoxide production**
MB cells were seeded on 96-well microplates (2,000 cells/well for ONS-76 and 9000 cells/well for HD-MB03) for 24 h and exposed to IR and/or β-blockers for 6 h. 3D spheroids of MB cells were formed 3 days before treatment, and exposed to IR and/or propranolol for 6 h. Superoxide anion production was assessed by adding 10% V/V of WST-1 reagent (Roche, ref. 11644807001) in the wells for 30 min at 37°C. Absorbance was measured at 450 nm with a PHERAtar® FS multi-plate reader. To normalise superoxide production to the cell number in each condition, cells were fixed with 1% glutaraldehyde and stained with a solution of 1% (W/V) crystal-violet in 20% methanol (Sigma-Aldrich). The dye has finally been solubilised in DMSO to measure absorbance at 600 nm.

**Colony formation assay**
Ninety-six-well microplates were coated with 1% agarose for 24 h. Two hundred and fifty ONS-76 cells and 500 HD-MB03 cells per well were then plated in a 10% Matrigel®- containing medium (Corning, ref. 354234) for 24 h and exposed to β-blockers and/or IR. Photos of the colonies were captured with the JuLI™ Stage imaging system and quantified using the Image J® software, 7 and 10 days after treatment initiation for ONS-76 and HD-MB03 cells, respectively.

**Analysis of energy metabolism**
Energy metabolism analysis was performed using the Seahorse XFe24® extracellular flux analyser (RRID:SCR_019539). Adherent MB cells were seeded in XF24 V7-PS plates (10,000 cells/well for DAOY; 12,000 cells/well for ONS-76 and UW228-2; 30,000 cells/well for HD-MB03; Agilent, ref. 102340-100) for 24 h. Two hundred ONS-76 cells and 9000 cells/well for HD-MB03 cells were seeded in XF24 HD-MB03 wells for ONS-76 and HD-MB03 cells, respectively.

Maximal mitochondrial respiration was measured after injection of FCCP. OCR-linked ATP production was calculated with difference between basal and maximal respiration values, while glycolytic reserve was calculated as the difference between oligomycin-enhanced and glucose-mediated ECAR values.

To normalise the data to cell number, cells were fixed with glutaraldehyde 1%, stained with violet crystal in 20% methanol (Sigma-Aldrich) and solubilised with DMSO to measure absorbance at 600 nm with PHERAtar® FS multi-plate reader. A calibration range established for each type of cell was finally used to convert the absorbance values into cell numbers.

**Quantitative RT-PCR analysis**
The expression of β1-, β2- and β3-adrenergic receptor genes (ADRB1, ADRB2 and ADRB3) was examined using real-time quantitative RT-PCR. Total cellular RNA was extracted from MB cells using the RNeasy Mini Kit according to the protocol supplied by the manufacturer (Qiagen, ref. 74104). RNA concentration was measured with the NanoVue™ Plus spectrophotometer (GE Healthcare Life Sciences). Reverse transcription of RNAs was done using Quantitect® Reverse Transcription kit (Qiagen, ref. 205311) and real-time PCR was run using the Quantitect® SYBR® Green PCR kit (Qiagen, ref. 204143) on a LightCycler®480 Instrument (RRID:SCR_020502). The primers were synthesised by Qiagen (QuantiTect® Primer Assay, ref. 249900) according to the sequences described in Cao DX et al.29 Gene expression level of ADRB1, ADRB2 and ADRB3 was determined using 2-ΔΔCt or 2-ΔCt method, normalised to GAPDH as housekeeping gene.

**siRNA transfection**
Small interfering RNAs directed against β1- or β2-adrenergic receptors (Silencer Select siRNA, ref. #4392420 - S1118, S1119 and S1120 for ADRB1 and S1121, S1122 and S1123 for ADRB2, ThermoFischer), and non-targeted SignalSilence® Control siRNA (Cell signaling, ref. #6568S) were transfected in MB cells using Lipofectamine™ 3000 (Invitrogen, ref. L1000015) according to the protocol supplied by the manufacturer. Verification of the successful transfection was performed by quantitative RT-PCR, as described above.

**RNA sequencing**
The MB cells ONS-76 WT, ONS-76 RP, ONS-76 RC and ONS-76 RN were homogenised using a Buffer RLT (Qiagen, ref. 79216) and DNA-free cell lysates were obtained using genomic DNA purification columns (Qiagen). Extraction of total RNA was performed using the RNeasy Plus Mini kit (Qiagen, ref. 74134), according to the protocol supplied by the manufacturer. RNA was sequenced using the 20x250mm DRAGEN SC1000 v2 instrument at the Oxford Nanopore Technologies facility (Oxford, UK).
quantified using a NanoVue™ Plus spectrophotometer (GE Healthcare Life Sciences). RNA-Seq libraries were generated from 600 ng of total RNA using TruSeq Stranded mRNA Library Prep Kit and TruSeq RNA Single Indexes kits A and B (Illumina), as previously described.33 The final cDNA libraries were checked for quality and quantified using capillary electrophoresis. Libraries were then sequenced on an Illumina HiSeq4000 sequencer (RRID:SCR_016186) as single end 1 × 50 base reads. Image analysis and base calling were performed using RTA 2.7.3 and bcl2fastq 2.17.1.14. Reads were preprocessed using Cutadapt v1.1011 in order to remove adapter, polyA and low-quality sequences (Phred quality score below 20), reads shorter than 40 bases were discarded for further analysis. Reads mapping to rRNA were also discarded (this mapping was performed using Bowtie v2.2.8.32 Reads were then mapped onto the hg38 assembly of human genome using STAR v2.5.3a.33 Gene expression was quantified using HT-SEQ-count. DESeq 2 (R/Bioconductor from Ensembl release 99. Statistical analysis was performed using R 3.3.2 and DESeq2 1.16.1 Bioconductor library.35 Read counts for ADRB1, ADRB2 and ADRB3 expression in primary MB samples from patients were produced by aligning paired end RNA-seq (~90 M read/sample Illumina HiSeq3500; RRID:SCR_020123) reads to HG19 genome using STAR-align.33 Read counts were produced using HT-SEQ-count. DESeq2 (R/Bioconductor) was used to normalise reads to library size and variance stabilised data (VSD) was generated using the vst function. Statistical testing for differential expression across groups was performed using an ANOVA test.

Ethics
Tumour samples from individuals with confirmed medulloblastoma diagnosis were used for RNA-seq analysis. These were provided as part of UK CCLG-approved biological study BS-2007-04 and/or with approval from Newcastle North Tyneside Research Ethics Committee (study reference 07/Q0905/71); informed, written consent was obtained from parents of all patients younger than 16 years.

All animals for PDX were housed in the animal facility of the Institut Curie, in accordance with the recommendations of the European Community (2010/63/UE) for the care and use of laboratory animals. Experimental procedures were specifically approved by the ethics committee of the Curie Institute CEEA-IC #118 (approval number: 03130.02, C91471108 and Authorisation APAFIS# 26879-202008131561665-v1 given by National Authority) in compliance with the international guidelines. Cerebellar explants were obtained from the animal facility of the Faculty of Pharmacy, in accordance with the recommendations of the European Community (approval number: E 13 055 20).

Statistics
All experiments were performed in independent replicates and statistical significance was determined by ANOVA or student’s t test using the GraphPad Prism 6 software (RRID:SCR_002798). A significant difference between two conditions is defined as: *p < 0.05, **p < 0.005, ***p < 0.001.

Role of funders
The study sponsors did not have any role in study design, in the collection, analysis, interpretation of data, in the writing of the manuscript or in the decision to submit it for publication.

Results
β-blockers inhibit the proliferation and survival of MB cell lines and patient-derived tumour cells
To determine the anti-proliferative properties of three different β-blockers with different selectivity profiles for adrenergic receptors — i.e., non-selective β-blocker propranolol, mixed α/β-blocker carvedilol and β1-selective antagonist nebivolol —, we first used a panel of six human MB cell lines characteristic of group 2 SHH (UW228-2 and DAOY) and non-WNT/non-SHH group (HD-MB03, ONS-76, D283 Med and D341 Med) tumours. All tested β-blockers inhibited the proliferation of MB cells, irrespective of their group (Figures 1a-c), with IC50 values ranging from 60-120 µM for propranolol, 12-15 µM for carvedilol and 13-15 µM for nebivolol (Table 1). We further showed that the activity of β-blockers results from both the inhibition of cell growth and the induction of cell death in murine SHH-MB cells (Figure S1a-f). To evaluate the three β-blockers in more clinically relevant cellular models, we cultured primary cells from group 3 and SHH patient-derived xenografts MB tumours (G3-PDX7 and SHH-PDX12, respectively). We confirmed the dose-dependent efficacy of propranolol, carvedilol and nebivolol in inhibiting cell survival of these PDX-derived cells (Figures 1d-f), as well as their ability to inhibit cell proliferation and induce cell death (Figure S1g-l).

β-blockers enhance IR-mediated inhibition of MB cell proliferation and clonogenicity
To study the combination between β-blockers and radiotherapy in MB cells, we first tested a single co-treatment of IR at 2, 5 or 10 Gy and low concentrations — IC50 — of propranolol, carvedilol or nebivolol. Results showed that the addition of the β-blockers led to a two-fold reduction in the dose of IR while maintaining the same activity in HD-MB03 cells (Figure 2a). For example, irradiation at 2 Gy combined with IC50 propranolol is as effective in reducing cell survival as irradiation alone at 5 Gy. IR potentiation by propranolol was also found in
ONS-76 cells (Figure 2b) and in the three other tested MB cell lines (Figure S2a-c). Similar effects were observed with low concentrations of carvedilol or nebivolol combined to IR in the different MB cell lines (Figures 2a-b and Figure S2a-c). To better explore the potential of these combinations in MB cell radiosensitivity, we conducted clonogenic assays. HD-MB03 and ONS-76 cells were exposed to propranolol and/or IR at 1.8 Gy, which is the daily radiation dose the most widely used in the clinic. As expected, the number of colonies was reduced by IR by 64 ± 5 % and 60 ± 5 % in HD-MB03 and ONS-76 cultures, respectively (Figures 2c-d). Our results also demonstrated that propranolol decreased the clonogenicity of MB cells, in a dose-dependent manner and significantly enhanced the efficacy of IR (Figures 2c-d and Figure S2d). For instance, the clonogenic capacity of HD-MB03 and ONS-76 cells exposed to the combination of IR with propranolol IC20 was reduced by 86 ± 3 % and 82 ± 3 %, respectively (Figures 2c-d, *p < 0.001 vs control).

To confirm the interest of such a combination in 3D tumour micromasses, we developed tumour spheroid models from MB cells stably expressing DsRed. For five consecutive days, spheroids were exposed to daily low doses of β-blockers alone or in combination with IR at carvedilol and nebivolol sustainably potentiate IR in HD-MB03 spheroids, as compared with IR alone (Figures 3a-d). While IR did no longer significantly impact the spheroid growth at day 21 (2317 ± 60 % growth in irradiated versus 2206 ± 79 % growth in control spheroids; *p > 0.05), the co-treatment with propranolol, carvedilol and nebivolol decreased the spheroid growth to 724 ± 5 %, 335 ± 2 % and 292 ± 5 %, respectively (*p < 0.001, Figures 3a-d). Similar results were obtained in ONS-76 spheroids (Figure S3a). In addition, β-blockers were able to restore IR efficacy in UW228-2 and D283 Med spheroids that were unresponsive or minimally responsive (Figure S3b-c) and they could further increase IR efficacy against the highly radio-sensitive D341 Med spheroids (Figure S3d). Finally, to evaluate the efficacy of daily co-treatment on primary MB cells, we established 3D neurospheres from the G3-PDX7 cells. Our results confirmed that low
concentrations of propranolol, carvedilol, or nebivolol highly potentiated the effects of IR (Figure 3e). The use of a second group 3 PDX model (G3-PDX3) further validated the relevance of combining \(\beta\)-blockers in co-treatment with daily radiotherapy in MB (Figure S3e). Altogether, our results demonstrated that \(\beta\)-blockers can improve the efficacy of IR in in vitro MB models.

Fractionated IR is potentiated by daily low doses of \(\beta\)-blockers in cerebellar organotypic models

To evaluate the potential of the \(\beta\)-blockers and IR combination in more clinically relevant conditions, we developed an organotypic cerebellar model in which MB spheroids stably expressing DsRed were grafted into slices of healthy mouse cerebellum. These innovative cultures were daily exposed to IR (1–8 Gy) and/or very low concentrations of propranolol (1 \(\mu\)M) for five consecutive days. After seven days, our data showed that monotherapies reduced the growth of HD-MB03 tumour masses by 23 \(\pm\) 5\% and 27 \(\pm\) 5\% in organotypic models subjected to IR and propranolol, respectively (\(p < 0.001\) and \(p < 0.05\), respectively; Figures 4a–b). The combinatorial treatment resulted in a reduction of 38 \(\pm\) 6\% (\(p < 0.001\) compared with control), which significantly increased the efficacy of IR (\(p < 0.001\), Figures 4a–b). The potentiating effect persisted over time, with the combination reducing tumour growth by 57 \(\pm\) 6\% after 14 days (\(p < 0.001\) vs control and \(p < 0.05\) vs IR; Figures 4a–b). The benefits of combining propranolol with IR were also confirmed in organotypic cerebellar models transplanted with ONS-76 tumour masses (Figure S4a–b). After 14 days, the organotypic cultures were fixed, sectioned, and subjected to HES and Ki67 staining (Figure 4c). Microscopic analysis of these labelling patterns showed that the combinatorial treatment did not induce histological lesions in the non-tumour cerebellar tissue, including in the MB periphery. Furthermore, \(\gamma\)H2AX staining of the organotypic models showed that the co-treatment with IR and propranolol did not induce DNA damage in the non-tumour tissue either (Figure 4c, Table 2, and positive control in Figure S4c). This suggests that the combination is effective in significantly reducing MB tumour mass without inducing additional damage to the cerebellum.

\(\beta\)-blocker efficacy and potentiation of IR are independent of \(\beta\)-adrenergic receptors in MB cells

The strong synergism between IR and \(\beta\)-blockers in MB stresses the need for a better understanding of the underlying mechanism(s). Since \(\beta\)-blockers antagonise the \(\beta\)-adrenergic receptors (\(\beta\)-ARs) in the cardiovascular system, we first evaluated the expression pattern of
β-AR genes *ADRB1*, *ADRB2* and *ADRB3* in MB tumours from a cohort of 240 patients (Figures 5a-c). While there are significant differences in expression of β-AR isoforms across MB groups (each *p* < 0.001), the median expression of *ADRB2* is the highest, followed by *ADRB1*, and WNT MB are the only samples that express
high levels of ADRB3. Kaplan Meier and Cox regression analyses revealed that high expression (>median) of ADRB1 and ADRB2 were associated with a good prognosis in a cohort of 222 patients (Figures 5d-f). We then quantified β-AR mRNA levels in the six human SHH and non-WNT/non-SHH group MB cell lines studied. Consistently with the results obtained with patient samples, ADRB2 and ADRB3 are the major and the minor
isomerism across the panel of cell lines, respectively (Figure 5g). Interestingly, despite being as sensitive as the other cell lines to the β1-selective antagonist nebivolol (Figure 1c), neither the DAOY nor the D341 Med cell lines express ADRB1 (Figure 5g). This suggests that the efficacy of β-blockers in MB cells may not rely on the canonical β-adrenergic pathway. To confirm this hypothesis, we silenced ADRB1 and ADRB2 in HD-MB03 and ONS-76 cells using RNAi technology (Figure S3a-b). β1-AR not being a target of any of the three β-blockers tested here. Our data showed that the efficacy of propranolol, carvedilol and nebivolol alone or in combination with IR was not impacted by β-AR silencing (dotted vs. solid lines, Figure 5h and Figure S5c-g). Moreover, β-AR siRNA did not improve the effects of IR alone in HD-MB03 cells, regardless of the dose used (Figure 5h and Figure S5c-d). In ONS-76 cells, β-AR silencing even significantly reduced the effects of IR (p < 0.05; Figure S5c-g). These results indicate that β-ARs are neither involved in β-blocker-induced cytotoxicity nor in radio-sensitisation of MB cells and support the idea that β-blockers trigger an alternative signaling pathway to potentiate radiotherapy in MB cells.

Response to β-blockers is associated with inhibition of energy metabolism in MB cells

Our previous work in triple-negative breast cancer has highlighted the ability of propranolol to affect energy metabolism pathways in tumour cells.10 To determine whether β-blockers disrupt the energy metabolism in MB cells, we characterised their bioenergetic profiles by measuring the mitochondrial respiration via the oxygen consumption rate (OCR) and the glycolytic activity via the extracellular acidification rate (ECAR), β-blocker treatment induced a significant drop in mitochondrial respiratory functions in ONS-76, HD-MB03, UW228-2 and DAOY cells, regardless of their initial bioenergetic status (Figure 6a and Figure S6a). Indeed, our data showed a decrease in both basal and maximal respiration after 24 h treatment with propranolol, carvedilol and nebivolol, for concentrations ranging from IC50 to IC80 (Figures 6b-c). As a result, ATP production was strongly reduced in all four MB cell lines exposed to the three β-blockers, even at the lowest concentrations (Figure 6d and Figure S6b, d, f). In addition, we demonstrated that incubation with propranolol, carvedilol and nebivolol led to a decrease in the glycolytic reserve in ONS-76, HD-MB03, DAOY and UW228-2 cells (Figure 6e and Figure S6c, e, g). Thus, treatment with β-blockers results in a metabolic catastrophe that deprives MB cells of their adaptive bioenergetics capacities.

To better understand the importance of bioenergetics in response to treatment, we generated β-blocker-resistant ONS-76 cells by exposing them to increasing concentrations of propranolol, carvedilol or nebivolol for 16 weeks (Figure S7a). The resulting cell lines i.e., ONS-76 RP, ONS-76 RC and ONS-76 RN, were cross-resistant to all β-blockers (Figure S7b). By qRT-PCR, we showed that the expression of β-AR genes was not altered in these resistant cells (Figure S7c). RNA sequencing further indicated that cell resistance could not be explained by the downregulation of key genes of the β-AR downstream signaling and its transcriptional targets (Figure S7d). Although four of the ten isoforms of adenylate cyclase are overexpressed in ONS-76 RP cells (ADCY1, 2, 5 and 8; p < 0.001), this pattern of overexpression was not found in ONS-76 RC and ONS-76 RN and therefore may not be the common factor behind the cross-resistance of the cell lines to beta-blockers. Analysis of the metabolic energetic activities in the three β-blocker resistant cell lines showed that they had higher mitochondrial OCR and ATP production than the sensitive parental ONS-76 WT cells (p < 0.001, Figures 7a-b and Figure S7c), but no significant changes in glycolytic capacity (Figures 7c-d). However, as illustrated with ONS-76 RC cells exposed to IC50 of propranolol, carvedilol or nebivolol, resistant cells were able to counteract both the β-blocker-mediated suppression of ATP production by mitochondria and glycolytic reserve (Figures 7e-f).

Lastly, we measured the effects of the combination of β-blockers and IR on the bioenergetics of MB cells. This analysis was performed at short time point (6 h) and with low doses of propranolol (IC10 and IC20) to better examine the effects of the combinatorial treatment. Propranolol alone and IR alone (1.8 Gy) did not significantly affect ATP production nor glycolytic reserve of HD-MB03 cells in these conditions (Figures 7g-h). Nevertheless, IR combined with IC50 propranolol inhibited the two processes by 39 ± 5 % and 63 ± 11 % respectively, as compared with IR monotherapy (p < 0.05, Figures 7g-h). This potentiation was also confirmed in ONS-76 cells (Figure S7f-g). Our results thus support the importance of bioenergetic disturbances in the response of MB cells to β-blockers and their combination with radiotherapy.

Table 2: γH2AX positive cells (% ± SD) in the cerebellum of the organotypic models. Quantification was made by microscopic analysis in the Neuropathology Department. p values > 0.05 indicate no significant variations.

|          | %    | SD   | p     |
|----------|------|------|-------|
| Control  | 1.6  | 1.34 | /     |
| Propra IC10 | 1.6 | 1.30 | 0.49  | vs Control |
| IR 1.8 Gy | 2.0  | 1.00 | 0.30  | vs Control |
| IR + Propra | 1.2 | 0.63 | 0.28  | vs Control |
|          |      |      | 0.08  | vs IR    |

β-blockers enhance IR-induced oxidative stress and consequently increase DNA damage in MB cells

Reactive oxygen species (ROS) are the major effectors of IR, contributing substantially to radiation-induced DNA
damage and cancer cell death. Given the effects of co-treatment on mitochondrial energy metabolism, we first determined whether the combination therapy could disrupt redox balance, by assessing the superoxide ion levels. Six hours post-irradiation, an expected increase in superoxide relative level of 34 ± 4% was observed in IR HD-MB03 cells compared to control cells (p < 0.001, Figure 8a). Propranolol, at 10 μM (IC50) and 25 μM (IC10), also increased the production of ROS by 36 ± 12% and 31 ± 9%, respectively (p < 0.01, Figure 8a).

Figure 5. β-Adrenergic receptors (β-AR) are not involved in the response of MB cells to β-blockers. Boxplot showing expression of ADRB1 (a), ADRB2 (b) and ADRB3 (c) by subgroup in MB patient cohort (n = 240). Kaplan-Meier curves reporting patient overall survival stratifying patients by > median and < median expression for ADRB1 (d), ADRB2 (e) and ADRB3 (f) expression levels. (g) Relative gene expression of ADRB1, ADRB2 and ADRB3 quantified by qRT-PCR using GAPDH as housekeeping gene (n = 8 per condition, from four independent experiments). Calculation has been done by the 2^ΔΔCt method. Values are the average of independent experiments ± standard error of mean (SEM). (h) Cell viability analysis by using the Alamar Blue assay after 72h of treatment with radiotherapy (IR) 1, 8, 5 and 10 Gy and increase concentrations of propranolol in HD-MB03 cells transfected with siRNA control (Ctl) or siRNA ADRB1&2. Values are the average of three independent experiments ± SEM, with a biological triplicate in each experiment. *p < 0.05; **p < 0.005; ***p < 0.001.
**Figure 6. β-blockers inhibit MB cell energy metabolism.** (a) Metabolic profile of MB cells before (Ctl) and after a 24 h treatment with IC50 of propranolol (propra) or carvedilol (carve). Mitochondrial respiration (OCR, oxygen consumption rate) and glycolytic activity (ECAR, extracellular acidification rate) were measured with the Seahorse XFe24™ analyser. Values are the average of at least six independent experiments ± standard error of mean (SEM). Basal respiration (b), maximal respiration (c), ATP production (d) and glycolytic reserve (e) of ONS-76 cells exposed for 24 h to increasing concentrations of propranolol (propra), carvedilol (carve) or nebivolol (nebi). Values are the average of three independent experiments ± SEM, with a biological duplicate in each experiment. ECAR and OCR were normalised to cell number. *p < 0.05; **p < 0.005; ***p < 0.001.
Figure 7. MB cells resistant to β-blockers are not sensitive to the treatment-mediated alteration of energy metabolism. Mitochondrial oxygen consumption rate (OCR) (a) and ATP production (b) in β-blocker sensitive cells (ONS-76 WT) and in three β-blocker resistant cells (ONS-76 RP, ONS-76 RC, ONS-76 RN), measured using the Seahorse XFe24® analyser. Glycolytic extracellular acidification rate (ECAR) (c) and glycolytic reserve (d) in β-blocker sensitive cells (ONS-76 WT) and in β-blocker resistant cells (ONS-76 RP, ONS-76 RC, ONS-76 RN), measured using the Seahorse XFe24® analyser. ATP production (e) and glycolytic reserve (f) measured with the Seahorse XFe24® analyser in sensitive and carvedilol resistant cells (ONS-76 RC) exposed to IC20 of propranolol (propra), carvedilol (carve) or nebivolol (nebi) for 24 h. ATP production (g) and glycolytic reserve (h) measured by using the Seahorse XFe24® analyser in HD-MB03 cells exposed for six hours to radiotherapy (IR) 1.8 Gy or IC10-IC20 of propranolol (propra) alone and their combination. All the values are the average of four independent experiments ± standard error of mean (SEM), with a biological triplicate in each experiment. Data were normalised to cell number. *p < 0.05; **p < 0.005; ***p < 0.001.
The combination of IR with these low doses of propranolol led to an additional upregulation of ROS levels, up to 64 ± 4 % and 59 ± 5 %, respectively (Figure 8a, p < 0.001). These results were confirmed with carvedilol at 5 (IC50) and 7.5 µM (IC20) in HD-MB03 cells (Figure S8a), as well as in MD 3D spheroids (Figure S8b, c). A significant overproduction of superoxide ions of 96 ± 6 % (p < 0.001) and 78 ± 7 % (p < 0.01) was also found in ONS-76 cells exposed to IR and combined with IC50 of propranolol or IC50 of carvedilol (Figure 8b). However, in the β-blocker-resistant cells ONS-76 RC, both propranolol and carvedilol were unable to amplify the effects of IR on superoxide production (Figure 8b). Potentiation of IR efficacy by the
two β-blockers was also significantly reduced in these cells (Figure S8b), supporting a tight link between ROS production and response of MB cells to the combinatorial treatment.

As the overproduction of ROS may contribute to an increase in cyclooxygenase 2 (COX-2) expression, which has been associated with the acquisition of a secondary radioresistance by tumour cells, we ensured that such a feedback loop was not triggered in MB cells. By analysing COX-2 relative expression level in HD-MB03 cells 24 h after treatment, we showed that it was reduced from 1.7 ± 0.3 in 1.8 Gy irradiated cells to 0.8 ± 0.1 and 0.7 ± 0.1 in cells subjected to IR combined with IC5 and IC10 propranolol respectively (p < 0.05, Figure 8c). The inhibition of IR-mediated increase in COX-2 expression by the combinatorial treatment was confirmed in ONS cells (Figure S8c).

Lastly, we evaluated the phosphorylation level of H2AX, being an early response to DNA double-strand breaks that here may be caused following ROS exposure. In HD-MB03 cells, 4 h after treatment, IR triggered the expected accumulation of γH2AX, as did low concentrations of propranolol (Figure 8d). Our results also showed a significant increase in γH2AX relative level from 2.7 ± 0.4 in irradiated cells to 8.6 ± 0.9 and 6.3 ± 0.7 in cells exposed to the co-treatment with IC1 and IC10 propranolol, respectively (p < 0.001, Figure 8d). By scavenging the superoxide ions (Figure 8a), Mito-TEMPO (MT) counteracted the increase in γH2AX level by the combinatorial treatments — which dropped to 2.0 ± 0.4 and 2.6 ± 0.2, respectively — (p < 0.01 and 0.05 vs co-treatments, respectively, Figure 8d). Likewise, scavenging of free radicals by Troxerutin (TROX; Figure 8a) led to a significant reduction in IR-mediated γH2AX accumulation (p < 0.05 vs co-treatments, Figure 8d). Taken together, our results suggest that β-blockers can specifically modulate mitochondrial bioenergetics and ROS production in MB cells, thus priming them for IR-induced oxidative stress and DNA damage. Our results therefore show that the efficacy of the combination of IR with β-blockers is, at least in part, based on a strong inhibition of MB cell bioenergetics, linked to the triggering of an endogenous oxidative stress.

Discussion

In recent years, many advances have been made in the management of children with MB. Nevertheless, a real concern remains the long-term sequelae due to the early exposure to toxic treatments. Drug repurposing appears to be a major tool to rapidly find effective and well-tolerated therapeutic approaches in oncology. It might especially be an alternative strategy to manage rare cancers such as paediatric tumours. Cardiovascular regulators, anti-helminthic drugs and non-steroidal anti-inflammatory drugs have recently shown to reduce MB tumour cell progression in vitro and in vivo. Here, we evaluated in MB models propranolol, carvedilol and nebivolol, which are lipophilic β-blockers that can cross the blood-brain barrier, and enter the cerebrospinal fluid and intracranial tissue.

Our results showed that the three β-blockers potentiate the efficacy of IR in a panel of MB cells, PDX cells and spheroid micromasses, including those poorly responsive to radiation. These results are consistent with the recent study from Chaudhary et al., that described a propranolol-mediated sensitisation to IR in non-small cell lung cancer cells in vitro. Enhanced effectiveness of IR at reducing the growth of gastric adenocarcinoma in vivo when combined with propranolol was also shown recently. Retrospective clinical studies have also shown that the combination of β-blockers and radiotherapy did not result in increased toxicities in patients with lung cancer and brain tumors such as meningioma. The interest of combining radiotherapy with β-blockers is further supported by the fact that -blockers are largely known to be good brain protectors that can be used for instance after head trauma including in children.

In response to the ever-increasing need to find alternatives to animal experimentation, we have developed an innovative organotypic cerebellum model in which MB tumour progression has been analysed over time. These ex vivo tissue cultures are described as highly relevant models to study the evolution of pathologies and to test their response to different therapeutic strategies, including in MB. We further showed that the dose of IR can be significantly reduced while maintaining treatment efficacy in MB cells by adding β-blockers. As the severity of cognitive damages in patients correlates with radiation doses, this suggests that combining β-blockers with IR may help limit treatment side effects.

One of the advantages of repurposing β-blockers as anti-cancer agents is that they can be translated to the clinic without the need for extensive preclinical studies, including in vivo experiments. For instance, propranolol was first used in a clinical setting in combination with metronomic chemotherapy in patients before it was later confirmed to be active in vivo in mouse models. In addition, an ongoing clinical trial (NCT04682158) exploring the combination of propranol with chemo-radiation is based on in vitro experiments and retrospective clinico-epidemiological experience in patients who received β-blockers for non-cancer purposes in combination. Another potential example is based on multiple myeloma for which clinical trials have been completed (NCT02420223) or recently initiated (NCT02420223) without myeloma-specific in vivo data but based but again on in vitro and clinic-epidemiological experiments. The results of the present article can thus provide a strong basis for initiating an early phase clinical trial.

The literature is divided regarding the mechanisms responsible for the anti-tumour properties of β-blockers.
Inhibition of the β-adrenergic signaling pathway has been suggested to be involved in propranolol activity in pancreatic cancer cells. Studies in angiosarcoma cells provide a good illustration of the conflicting hypotheses. Amaya et al. proposed the involvement of the β-adrenergic pathway in the mechanism of action of propranolol, whereas a recent study by Overman et al. argued the opposite and showed a key role for the SOX18 protein in the response to the β-blocker. In the paediatric tumours neuroblastoma and hemangioma, the results agree that β-ARs are not responsible for the anti-tumour efficacy of β-blockers, showing that the R-enantiomer of propranolol – which has very low affinity for β-ARs – has the same efficacy as the S-enantiomer that is highly affine for the receptors. Although patient MB biopsies showed detectable β-AR expression, we demonstrated herein that their silencing did not alter the efficacy of propranolol, carvedilol and nebivolol in MB cells, suggesting that the efficacy of β-blockers in MB cells may not result from the inhibition of the canonical targets.

We and others have reported that propranolol-exposed cancer cells were sensitised to the metabolic stress induced by metformin, rapamycin, 2-deoxy-D-glucose or dichloroacetate. Here, we showed that the activity of the β-blockers in MB cells was driven by a rapid disruption of the mitochondrial bioenergetics, which led to a sustained accumulation of ROS. This is consistent with the alteration of the mitochondrial fusion/fission balance that we previously observed in neuroblastoma cells treated with propranolol. The significance of cancer cell energy metabolism in response to β-blockers is further strengthened by the fact that the lack of impact on mitochondrial and glycolytic pathways results in resistance of MB cells to these repurposed drugs.

Efficacy of radiation therapy relies on its ability to cause DNA breaks and to subsequently trigger cell death. The DNA damages mainly result from the generation of ROS, such as superoxide and hydroxyl radicals, during H₂O radiolysis. Here, we showed that β-blockers potentiate IR-mediated DNA damages in MB cells by increasing superoxide accumulation. Our results are consistent with the fact that pharmacologic depletion of glutathione, which belongs to the cell antioxidant system, significantly results in radiosensitisation of cancer stem cells. Recently, Gd-doped titania nanoparticules that target mitochondria to enhance ROS accumulation were also shown to sensitise breast cancer cells to radiotherapy-induced apoptosis in vitro and in vivo. Increasing ROS levels in MB tumour cells during radiotherapy may thus significantly enhance the efficiency and decrease the dosage of radiation.

COX-2 overexpression has been associated with resistance to IR in prostate, lung and oral squamous cancer cells. Conversely, COX-2 inhibitors can synergise with IR in inducing apoptosis, including in MB stem-like cells. COX-2 inhibition has been suggested as a potential strategy in MB to decrease the production of prostaglandin E₂ (PGE₂) and ultimately promote tumour cell death. Here, we showed that propranolol prevented the increase in COX-2 expression mediated by IR, but the involvement of the PGE₂ pathway in improving response of MB cells to combinatorial therapy remains to be better characterised.

To conclude, our work highlights the interest of channeling the ability of β-blockers to inhibit mitochondrial bioenergetics to design new therapeutic combinations with radiotherapy that lower the dose while maintaining anti-tumour activity. Given the few druggable molecular targets identified in non-WNT MB and the fact that young age of patients limits treatment options, our work proposes an alternative approach in which drug repurposing could be quickly translated to the clinic to improve the efficacy of radiotherapy and/or decrease its toxicity.

Contributors
Conceptualisation: E.P., M.C. and N.A. Formal analysis: M.R., J.T., M.M., N.A., D.W. Funding acquisition: N.A., M.R. and M.C. Methodology: J.T., C.K., D.B., L.P., P.P., M.-P.M., E.A.-C., R.A. and V.B. Project administration: M.C., S.C., O.A. and N.A. Supervision: M.C. and N.A. Validation: M.R., O.A., J.T., M.L.G., P.P., E.P., D.B., M.-P.M. and M.M. Writing, review & editing: M.R., M.C., E.P., D.B., M.-P.M., E.A.-C., M., R.A. and V.B. Project administration: M.C., S.C., O.A. and N.A. Supervision: M.C. and N.A. Validation: M.R., O.A., J.T., M.L.G., P.P., E.P., D.B., M.-P.M. and M.M. Writing, review & editing: M.R., M.C., E.P., D.B., M.-P.M., E.A.-C., M., R.A. and V.B.

Declaration of interests
The authors have declared no conflict of interest.

Acknowledgements
We would like to thank Julie Desrousseaux, Sophie Capdeville and Stephanie Gempp for their availability and help in irradiating cells, Samy Vigier and Anne Rodallec for their help with animal experimentation, and Camille Cordero for defining the conditions of cell irradiation. We also thank Claire Lovo and Marie-Noëlle Soler from the Light Microscopy facility of Multimodal Imaging Center (CNRS UAR2016/Inserm US43/Institut Curie/Université Paris-Saclay), for IncuCyte imaging assistance, Christophe Alberti and Elodie Belloir for...
Supplementary material

Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.ebiom.2022.104149.

References

1. Schwabke EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet 2017;7:785–791.
2. Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature 2017;547(7663):311–317.
3. Sharma T, Schwabke EC, Williamson D, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 1 and Group 4 subtypes. Acta Neuropathol (Berl). 2019;138(3):309–326.
4. Massimino M, Biassoni V, Gandola L, et al. Childhood medulloblas-
toma. Crit Rev Oncol Hematol. 2016;95:35–57.
5. Jurachka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review. J Neurosurg Pediatr. 2019;24(4):353–365.
6. Ward E, DeSantis C, Robbins A, et al. Neurocognitive conse-
tquences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. Off J Am Soc Clin Oncol. 2019;37(12):101084.
7. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive conse-
tquences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. Off J Am Soc Clin Oncol. 2019;37(12):101084.
8. Lafay-Lebourg N, Street J, Pouchy C, et al. Effective management of beta-adrenoceptor antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer. J Clin Med. 2019;8(1). [cited 2020 Apr 15].
9. Chen M, Qiao G, Hylander BL, et al. Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation. Nat Commun. 2020;11(1):1821–1832. https://doi.org/10.1038/s41467-020-15676-0.
10. Li X, Che X, Zhao W, et al. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol Lond Engl. 2010;5:98.
11. Li X, Chauvat H, Qiu G, Che X, Fan L. The role of propranolol as a radiosensitizer in gastric cancer treatment. Drug Des Devel Ther. 2018;12:631–645.
12. Pintev B, Kinne TM, Baumert BG, Boström J. Earlier and sustained response with incidental use of cardiovascular drugs among patients with low-to-medium-grade meningiomas treated with radiosurgery (SRS) or stereotactic radiotherapy (SRT). Radiother Oncol. 2014;111(1):446–450.
13. Wang HM, Liao ZY, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013;24(1):111–115.
14. Zindy F, Uszel T, Ayroud O, et al. Genetic alterations in mouse medul-
loblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res. 2007;67(6):2676–2684.
15. Garancher A, Lin CY, Morabito M, et al. NLR and CRX define pho-
totypes and identity and reveal subgroup-specific dependencies in medulloblastoma. Cancer Cell. 2018;33(3):435–449.e6.
16. Ariey-Bonnet J, Carrasco K, Le Grand M, et al. In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibi-
tor. Mol Oncol. 2020;14(12):2083–2099.
17. xing Cao D, hao W, ang Yang Z, et al. Role of beta1-adrenocep-
tor in increased lipolysis in cancer cachexia. Cancer Sci. 2010;101 (7):1659–1665.
18. Henriques A, Huebeker M, Blasco H, et al. Inhibition of beta-glucog-
sel activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2017;7:2513.
19. Martin M. Cutadapt removes adapter sequences from high-
througput sequencing reads. EMBnet.journal. 2011;17(1):10–12.
20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–359.
21. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrastar universal RNA-seq aligner. Bioinformatics. 2013;30(15):211–212.
22. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–167.
23. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
24. Rico M, Bagliani M, Bondarenko M, et al. Metformin and proprana-
ol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017;8(24):2874–2889.
25. Srivinas US, Tan BWQ, Vellayappan BA, Jayasekaran AD. ROS and the DNA damage response in cancer. Redox Biol. 2018;21:10084.
26. Cheng W, Flaherty KT. Does lipidophily matter? Basic Res Cardiol. 2000;95 (suppl 1):141–145.
41 Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. *Ann Oncol*. 2013;24(3):1132–1139.

42 Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. *Ann Oncol Off J Eur Soc Med Oncol*. 2013;24(5):1132–1139.

43 Zeeshan M, Hamidi M, O’Keeffe T, et al. Propranolol attenuates cognitive, learning, and memory deficits in a murine model of traumatic brain injury. *J Trauma Acute Care Surg*. 2019;87(3):1140–1147.

44 Fumagalli C, Maurizi N, Marchienni N, Formasari D. β-blockers: their new life from hypertension to cancer and migraine. *Pharmacol Res*. 2020;154:104587.

45 Meijer TG, Naipal KA, Jager A, van Gent DC. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. *Future Sci OA*. 2017;3(2):FSO192.

46 Bindra RS, Wolden SL. Advances in Radiation Therapy in Pediatric Vascular Syndrome and Hemangioma. *Future Sci OA*. 2017;3(2):FSO190.

47 Banavali S, Pasquier E, Andre N. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. *Eur J Cancer*. 2015;53:499–502. https://doi.org/10.1016/j.ejca.2015.04.003.

48 Stiles JM, Amaya C, Rains S, et al. Targeting of beta adrenergic receptor β2 in mouse neuroblastoma: implications for cancer therapy. *Pediatr Dev Pathol*. 2011;14(1):70–76.

49 Farrugia MK, Ma SJ, Flaherty L, Repasky EA, Singh AK. Concurrent β-blocker use is associated with improved outcomes in esophageal cancer patients who undergo chemoradiation: a retrospective matched pair analysis. *Am J Clin Oncol*. 2020;43(2):285–294.

50 Hsu YL, Shi Q, Kumar SK, et al. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *Am J Hematol*. 2017;92(5):450–453.

51 Zhang D, Ma QY, Hu HT, Zhang M. β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. *Cancer Biol Ther*. 2010;11(5):292–299.

52 Amaya CN, Perkins M, Belmont A, et al. Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression-free- and overall-survival in patients diagnosed with metastatic angiosarcoma. *Oncoscience*. 2018;3(1):410–419.

53 Overman J, Fontaine F, Wylie-Sears J, et al. R-propranolol is a small molecule inhibitor of the SOX8 transcription factor in a rare vascular syndrome and hemangioma. *CLINIC*. 2019;8:43026–43040. https://doi.org/10.7754/eLife.43026.

54 Sasaki M, North PE, Elsey J, et al. Propranolol exhibits activity against hemangiomata independent of beta blockade. *NPJ Precis Oncol*. 2019;3:27–35. https://doi.org/10.1038/s41598-019-0099-9.

55 Seebauer CT, Graus MS, Huang L, McCann AJ, Wylie-Sears J, Fontaine FR, et al. Non-β-blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. *J Clin Invest*. 2021;132(4):151109–151123. https://doi.org/10.1172/JCI115110.

56 Brohi L, Demine S, Willems J, Arnauld T, Collie AC. Deroanne CF. Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. *Oncotarget*. 2015;6(13):11264–11280.

57 Brohi L, Peulen O, Nusgen B, et al. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. *Sci Rep*. 2016;8:7070.

58 Lucido CT, Miskimins WK, Vermeer PD. Propranolol promotes glucose dependence and synergizes with dichloroacetate for anti-cancer activity in HNSCC. *Cancers*. 2018;10(12):476.

59 Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature*. 2009;458(7239):780–784.

60 Chen Y, Li N, Wang J, et al. Enhancement of mitochondrial ROS accumulation and radiotherapeutic efficacy using a Gd-doped titanina nanosensitizer. *Theranostics*. 2019;9(1):167–178.

61 Anai S, Tanaka M, Shiverick RT, et al. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. *J Urol*. 2007;177(5):1913–1917.

62 Terakado N, Shintani S, Yano J, et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. *Oral Oncol*. 2004;40(4):383–389.

63 Han ZQ, Liao H, Shi F, et al. Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis. *Oncol Lett*. 2017;14(5):5951–5956.

64 Salehifar E, Hosseinzadeh SJ. The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers. *Drug Discov Today*. 2018;23(1):654–662.

65 Chen KH, Hsu CC, Song WS, et al. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. *Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg*. 2010;26(1):1605–1612.

66 Yang MY, Lee HT, Chen CM, Shen CC, Ma HI. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. *Int J Mol Sci*. 2014;15(6):11015–11029.

67 Baryawno N, Svennborjsson B, Eksborg S, et al. Tumor growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. *Neuro-Oncol*. 2008;10(5):561–574.